146 related articles for article (PubMed ID: 16239205)
1. Hypercalcemia and local production of parathyroid hormone-related protein by a perisellar rhabdomyosarcoma after remote pituitary irradiation.
Florez JC; Burton DW; Arnell PM; Deftos LJ; Klibanski A
Endocr Pract; 2005; 11(3):184-9. PubMed ID: 16239205
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia associated with squamous cell carcinoma of tongue.
Gavrila A; Hasinski S; Rose LI
Endocr Pract; 2001; 7(6):459-62. PubMed ID: 11747283
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
4. Congenital craniopharyngioma and hypercalcemia induced by parathyroid hormone-related protein.
Brown JL; Burton DW; Deftos LJ; Smith AA; Pincus DW; Haller MJ
Endocr Pract; 2007; 13(1):67-71. PubMed ID: 17360305
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein.
Loh K; Matthay KK; Hoover M; Bracho FA; Cortez AB; Conte FA; Albanese CT; Miller TR; Price DC; Flores AJ; Kaviani A; Shoback D
Horm Res; 1998; 50(4):217-21. PubMed ID: 9838243
[TBL] [Abstract][Full Text] [Related]
6. Hypercalcemia of malignancy.
Body JJ
Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
[TBL] [Abstract][Full Text] [Related]
7. The use of pamidronate in PTHrP associated hypercalcaemia in infancy.
Buckmaster A; Rodda C; Cowell CT; Ogle G; Dorney S
J Pediatr Endocrinol Metab; 1997; 10(3):301-4. PubMed ID: 9388823
[No Abstract] [Full Text] [Related]
8. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Shimizu H; Monden T; Tomotsune T; Nakatani Y; Domeki N; Matsumura M; Jojima T; Kawagoe Y; Kasai K
Intern Med; 2011; 50(24):2993-6. PubMed ID: 22185991
[TBL] [Abstract][Full Text] [Related]
9. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
10. Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Kurosawa M; Iwasaki H
Ann Hematol; 2002 Nov; 81(11):668-71. PubMed ID: 12454709
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia.
Wong K; Tsuda S; Mukai R; Sumida K; Arakaki R
Endocrine; 2005 Jun; 27(1):83-6. PubMed ID: 16077176
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia in children with rhabdomyosarcoma.
Kawasaki H; Takayama J; Nagasaki K; Yamaguchi K; Ohira M
J Pediatr Hematol Oncol; 1998; 20(4):327-9. PubMed ID: 9703006
[TBL] [Abstract][Full Text] [Related]
14. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
15. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
16. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
18. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
19. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
20. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
